Activin receptor-like kinase-2 inhibits activin signaling by blocking the binding of activin to its type II receptor

Journal of Endocrinology

Volumn 195, Issue 1, 2007, Pages 95-103

  Renlund, Nina ^a   O'Neill, Francis H ^a   Zhang, Li Hua ^a   Sidis, Yisrael ^a   Teixeira, Jose ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVIN A; ACTIVIN RECEPTOR 2; CAGA PROTEIN; CYTOCHROME P450C17; HORMONE RECEPTOR; IODINE 125; LUCIFERASE; MESSENGER RNA; MUELLERIAN INHIBITING FACTOR; MUELLERIAN INHIBITING FACTOR 2 RECEPTOR; SMALL INTERFERING RNA; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 2; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CELL SPECIFICITY; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME INHIBITION; GENE OVEREXPRESSION; ISOTOPE LABELING; LEYDIG CELL; MOLECULAR MECHANICS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEPTOR BINDING; REPORTER GENE; SIGNAL TRANSDUCTION;

ACTIVIN RECEPTORS, TYPE I; ACTIVIN RECEPTORS, TYPE II; ACTIVINS; ANIMALS; ANTI-MULLERIAN HORMONE; BLOTTING, WESTERN; CELL LINE, TRANSFORMED; IMMUNOPRECIPITATION; LEYDIG CELLS; MALE; MICE; PHOSPHORYLATION; PROTEIN BINDING; RECEPTORS, PEPTIDE; RECEPTORS, TRANSFORMING GROWTH FACTOR BETA; RNA INTERFERENCE; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; SMAD2 PROTEIN; STEROID 17-ALPHA-HYDROXYLASE; TRANSFECTION;

EID: 35848948207     PISSN: 00220795     EISSN: None     Source Type: Journal    
DOI: 10.1677/JOE-07-0281     Document Type: Article

References (27)

1. Ascoli M 1981 Characterization of several clonal lines of cultured Leydig tumor cells: gonadotropin receptors and steroidogenic responses. Endocrinology 108 88-95.
2. Attisano L, Carcamo J, Ventura F, Weis FM, Massague J & Wrana JL 1993 Identification of human activin and TGF beta type I receptors that form heteromeric kinase complexes with type II receptors. Cell 75 671-680.
3. Clarke TR, Hoshiya Y, Yi SE, Liu X, Lyons KM & Donahoe PK 2001 Mullerian inhibiting substance signaling uses a BMP-like pathway mediated by ALK2 and induces Smad6 expression. Molecular Endocrinology 15 946-959.
4. Dennler S, Itoh S, Vivien D, ten Dijke P, Huet S & Gauthier JM 1998 Direct binding of Smad3 and Smad4 to critical TGF beta-inducible elements in the promoter of human plasminogen activator inhibitor-type 1 gene. EMBO Journal 17 3091-3100.
5. Desgrosellier JS, Mundell NA, McDonnell MA, Moses HL & Barnett JV 2005 Activin receptor-like kinase 2 and Smad6 regulate epithelial-mesenchymal transformation during cardiac valve formation. Developmental Biology 280 201-210.
6. ten Dijke P, Yamashita H, Sampath TK, Reddi AH, Estevez M, Riddle DL, Ichijo H, Heldin CH & Miyazono K 1994 Identification of type I receptors for osteogenic protein-1 and bone morphogenetic protein-4. Journal of Biological Chemistry 269 16985-16988.
7. Donahoe PK, Ito Y & Hendren WH 1977 A graded organ culture assay for the detection of Mullerian inhibiting substance. Journal of Surgical Research 23 141-148.
8. Ebner R, Chen RH, Shum L, Lawler S, Zioncheck TF, Lee A, Lopez AR & Derynck R 1993 Cloning of a type I TGF-beta receptor and its effect on TGF-beta binding to the type II receptor. Science 260 1344-1348.
9. Gouedard L, Chen YG, Thevenet L, Racine C, Borie S, Lamarre I, Josso N, Massague J & di Clemente N 2000 Engagement of bone morphogenetic protein type IB receptor and Smad1 signaling by anti-Mullerian hormone and its type II receptor. Journal of Biological Chemistry 275 27973-27978.
10. Harrison CA, Gray PC, Koerber SC, Fischer W & Vale W 2003 Identification of a functional binding site for activin on the type I receptor ALK4. Journal of Biological Chemistry 278 21129-21135.
11. Jamin SP, Arango NA, Mishina Y, Hanks MC & Behringer RR 2002 Requirement of Bmpr1a for Mullerian duct regression during male sexual development. Nature Genetics 32 408-410.
12. Korchynskyi O & ten Dijke P 2002 Identification and functional characterization of distinct critically important bone morphogenetic protein-specific response elements in the Id1 promoter. Journal of Biological Chemistry 277 4883-4891.
13. Laurich VM, Trbovich AM, O'Neill FH, Houk CP, Sloss PM, Payne AH, Donahoe PK & Teixeira J 2002 Mullerian inhibiting substance blocks the protein kinase A-induced expression of cytochrome p450 l7alpha-hydroxylase/C(17-20) lyase mRNA in a mouse Leydig cell line independent of cAMP responsive element binding protein phosphorylation. Endocrinology 143 3351-3360.
14. Lin T, Calkins JK, Morris PL, Vale W & Bardin CW 1989 Regulation of Leydig cell function in primary culture by inhibin and activin. Endocrinology 125 2134-2140.
15. Lorenzo HK, Teixeira J, Pahlavan N, Laurich VM, Donahoe PK & MacLaughlin DT 2002 New approaches for high-yield purification of Mullerian inhibiting substance improve its bioactivity. Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences 766 89-98.
16. Macias-Silva M, Heedless PA, Tang SJ, Buchwald M & Wrana JL 1998 Specific activation of Smad1 signaling pathways by the BMP7 type I receptor, ALK2. Journal of Biological Chemistry 273 25628-25636.
17. Massague J & Chen YG 2000 Controlling TGF-beta signaling. Genes and Development 14 627-644.
18. Mauduit C, Chauvin MA, de Peretti E, Morera AM & Benahmed M 1991 Effect of activin A on dehydroepiandrosterone and testosterone secretion by primary immature porcine Leydig cells. Biology of Reproduction 45 101-109.
19. Mishina Y, Rey R, Finegold MJ, Matzuk MM, Josso N, Cate RL & Behringer RR 1996 Genetic analysis of the Müllerian-inhibiting substance signal transduction pathway in mammalian sexual differentiation. Genes and Development 10 2577-2587.
20. Oh SP, Seki T, Goss KA, Imamura T, Yi Y, Donahoe PK, Li L, Miyazono K, ten Dijke F, Kim S et al. 2000 Activin receptor-like kinase 1 modulates transforming growth factor-beta 1 signaling in the regulation of angiogenesis. PNAS 97 2626-2631.
21. Onichtchouk D, Chen YG, Dosch R, Gawantka V, Delius H, Massague J & Niehrs C 1999 Silencing of TGF-beta signalling by the pseudoreceptor BAMBI. Nature 401 480-485.
22. Piek E, Heldin CH & Ten Dijke P 1999 Specificity, diversity, and regulation in TGF-beta superfamily signaling. FASEB Journal 13 2105-2124,
23. Trbovich AM, Sluss PM, Laurich VM, O'Neifl-FH, MaeLaughlin DT, Donahoe PK & Teixeira J 2001 Mullerian inhibiting substance lowers testosterone in luteinizing hormone-stimalated rodents. PNAS 98 3393-3397.
24. Tsuchida K, Mathews LS & Vale WW 1993 Cloning and characterization of a transmembrane serine kinase that acts as an activin type I receptor. PNAS 90 11242-11246.
25. Visser JA, Olsso R, Verhoef-Post M, Kramer P, Thernmen AP & Ingraham HA 2001 The serine/threonine transmernbrane receptor ALK2 mediates Müllerian inhibiting substance signaling. Molecular Endocrinology 15 936-945.
26. Wang T, Li BY, Danielson PD, Shah PC, Rockwell S, Lechleider RJ, Martin J, Manganaro T & Donahoe PK 1996 The immunophilin FKBP12 functions as a common inhibitor of the TGF beta family type I receptors, Cell 86 435-444.
27. Yamashita H, ten Dijke P, Franzen P, Miyazono K & Heldin CH 1994 Formation of hetero-oligomeric complexes of type I and type II receptors for transforming growth factor-beta. Journal of Biological Chemistry 269 20172-20178.